Shares of InTest Corporation jumped 12.6% to $13.85 after the semiconductor test-equipment maker disclosed a preliminary Q3 update that blew past expectations — record orders, revenue tracking at the top of guidance, and a backlog that swelled by nearly a third. The question now: whether this small-cap name, still barely profitable, can convert a red-hot order book into the bottom-line results that justify a stock that has more than doubled from its late-2025 lows.
Record Orders Dwarf What the Company Can Ship Right Now
InTest expects Q3 orders of $48–$50 million, driven by record back-end semiconductor orders, producing an estimated book-to-bill ratio above 1.3x — meaning the company is booking far more work than it's delivering. Q3 revenue is expected at the high end of its $33–$35 million guidance, representing growth of more than 30% from $26.2 million a year ago. That gap between incoming orders and shipped revenue signals a pipeline that could fuel growth for several quarters — if customers don't cancel.
AI-Driven Chip Demand Is the Engine
CEO Rich Rogoff said the semiconductor demand the company anticipated for the second half "has materialized," with demand for advanced test solutions being driven by customers' capacity expansions fueled in part by AI-driven data-center demand. That ties InTest to one of the strongest spending cycles in tech, though the company remains a niche supplier — its market capitalization sits at roughly $228 million , a fraction of larger test-equipment peers.
A Swelling Backlog Anchors the Revenue Outlook, But Margins Are the Risk
Preliminary backlog at September 30 is estimated at $58–$60 million, up approximately 28%–32% from June 30. That provides strong revenue visibility. However, full-year gross margin guidance was lowered to roughly 43% from a prior 45% target , and trailing profit margin sits at just 0.75% on $128 million of trailing revenue. Converting orders into profitable revenue remains the central challenge.
Valuation Has Run Up Quickly
At a trailing price-to-earnings ratio of 454x and a forward P/E of roughly 21.6x , investors are pricing in a dramatic earnings ramp. The consensus Q3 EPS estimate is $0.117 , and meeting that would represent real progress. But with negative trailing operating and free cash flow and a disclosed material weakness in internal controls, execution risk hasn't disappeared. Full results on November 6 will reveal whether the order boom is translating into the margins shareholders need.